

## Task Force on Repurposing of Drugs (TFORD) for COVID-19

### Patent status in India: by GANLEX

#### Lopinavir + Ritonavir

#### A. Active patents - None

#### B. Pending applications

S.no.	Title	Assignee	Application details	Type of patent	Remarks
1.	Compositions Of Lopinavir And Ritonavir	The University Of Liverpool	App no: 513/MUMNP/2014 Priority date: 09/09/2011 Status: Under Examination	Nanoparticles of lopinavir and ritonavir dispersed within a mixture of at least one hydrophilic polymer and at least one surfactant	Can be worked around even if granted
2.	Capsule Compositions Comprising Lopinavir And Ritonavir	Hetero Labs Limited	App no: 201741046596 Priority date: 26/12/2017 Status: Request for examination not yet filed	A soft gelatine capsule composition comprising thermodynamically stable solution comprising 100mg to 200mg of lopinavir, 25mg to 50mg of ritonavir and amphipathic lipid	Can be worked around even if granted

#### C. Expired/Lapsed applications

S.no.	Title	Assignee	Patent/ Application details	Type of patent	Remarks
1.	Improved pharmaceutical formulations	Abbott Laboratories	App No: IN/PCT/2001/01312/MUM Filing Date: 22/10/2001 Status: Abandoned	Combination of lopinavir and ritonavir along with the use of organic solvent which comprises fatty acids	No patent barrier
2.	Solid pharmaceutical dosage form	Abbott Laboratories	App no: 339/MUMNP/2006 Filing Date: 24/03/2006 Status: Rejected by controller on 30/12/2010	Solid pharmaceutical dosage form	No patent barrier
3.	Solid pharmaceutical dosage form	Abbott Laboratories	App No: 726/MUMNP/2009 Filing Date: 15/04/2009 Status: Abandoned	Solid pharmaceutical dosage form	No patent barrier
4.	Solid pharmaceutical dosage form	Abbott Laboratories	App no: 2474/DELNP/2009 Filing Date: 15/04/2009 Status: Withdrawn	Solid pharmaceutical dosage form	No patent barrier
5.	An antiretroviral composition of lopinavir and ritonavir	Cipla Ltd	App no: 1269/MUM/2006 Filing Date: 10/08/2006 Status: No status available online. However, appears abandoned.	Composition lopinavir and ritonavir	No patent barrier

Commissioned by



## Task Force on Repurposing of Drugs (TFORD) for COVID-19

### Patent status in India: by GNANLEX

6.	Antiretroviral solid oral composition	Cipla Ltd	App no: 351/MUMNP/2009 Filing Date: 16/02/2009 Status: Abandoned	Solid oral composition comprising water insoluble polymer,	No patent barrier
7.	A solid pharmaceutical dosage formulation	Abbott Lab	APP NO: 6733/DELNP/2007 Filing Date: 30/08/2007 Status: Abandoned	Dosage forms comprising lopinavir and ritonavir in a ratio of 4:1.	No patent barrier
8.	Novel process for manufacture of lopinavir & ritonavir tablets	Toyama Chemical Co Ltd	Grant no:- 264695 App No: 496/MUM/2008 Filing Date: 11/03/2008 Status: Ceased on 11/03/2016	Pharmaceutical formulation containing Lopinavir and Ritonavir using additives, organic solvent and nonsolvent	No patent barrier
9.	Amorphous form of lopinavir and ritonavir mixture	Hetero Research Foundation	App No: 665/CHE/2011 Filing Date: 07/03/2011 Status: Abandoned	Amorphous Form of lopinavir and ritonavir mixture in the ratio of 3 : 1.2 to 4.2:0.8.	No patent barrier
10.	Solid antiretroviral composition for oral delivery	Vavia Pradeep Ratilal	App No: 2627/MUM/2011 Filing Date: 16/09/2011 Status: Abandoned	Pharmaceutical composition to achieve the stable, smaller and highly bioavailable oral solid dosage form	No patent barrier
11.	Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone	Hetero Research Foundation	App No: 2828/CHE/2011 Filing Date: 18/08/2011 Status: Abandoned	Amorphous mixture of lopinavir and ritonavir co-precipitated on copovidone	No patent barrier
12.	A process for the preparation of solid dispersion of lopinavir and ritonavir	Ranbaxy Laboratories Limited	App no: 3410/DEL/2011 Filing Date: 28/11/2011 Status: Abandoned	A solid dispersion of lopinavir and ritonavir.	No patent barrier

#### Disclaimer:

Search results are up to 1<sup>st</sup> April 2020

GNANLex's Opinion / Report as hereinabove is to the best of our knowledge, true and accurate as of the date compiled based on available information. However, no guarantee is made as to its accuracy, reliability or completeness. The final user is expected to assume sole liability for any patent infringement that occurs by following our recommendations or using the information given. Before using, user should determine the suitability of the information for his intended use. The risk and liability, if any, in connection therewith, is solely that of the user.

Commissioned by

